HSBC Holdings’s Soleno Therapeutics SLNO Stock Holding History

HSBC Holdings’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-174,204	Closed	-$5.83M	–	3185
2026 Q1	$5.83M	Buy	+174,204	New	+$6.83M	﹤0.01%	1120
2025 Q4	–	Sell	-123,951	Closed	-$8.38M	–	3140
2025 Q3	$8.38M	Buy	123,951 +120,048	+3,076%	+$8.9M	﹤0.01%	993
2025 Q2	$335K	Sell	3,903 -149,054	-97%	-$11.2M	﹤0.01%	2374
2025 Q1	$10.9M	Buy	+152,957	New	+$7.45M	0.01%	869

HSBC Holdings's SLNO Position: Q2 2026 in Review

HSBC Holdings sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 174,204 shares — an estimated $5.83M sold.

HSBC Holdings first reported a position in SLNO in Q1 2025 and held it in 4 quarters. The position peaked at $10.9M in Q1 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

HSBC Holdings reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
HSBC Holdings sold 174,204 Soleno Therapeutics shares in Q2 2026, an estimated $5.83M.
HSBC Holdings first reported a position in Soleno Therapeutics in Q1 2025 and held it in 4 quarters.
HSBC Holdings's Soleno Therapeutics position peaked at $10.9M in Q1 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.